QIAGEN N.V. (QGEN)
Why Qiagen (QGEN) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Qiagen N.V. (QGEN) Q3 2024 Earnings Call Transcript
Qiagen N.V. (NYSE:QGEN ) Q3 2024 Earnings Conference Call November 7, 2024 9:30 AM ET Company Participants John Gilardi - VP, Head of Corporate Communications and IR Thierry Bernard - CEO Roland Sackers - CFO Conference Call Participants Patrick Donnelly - Citi Odysseas Manesiotis - Berenberg Matt Sykes - Goldman Sachs Doug Schenkel - Wolfe Research Aisyah Noor - Morgan Stanley Michael Ryskin - Bank of America Casey Woodring - JP Morgan Andrew Brackmann - William Blair Operator Ladies and gentlemen, thank you for standing by.
QIAGEN Stock Flat Post Q3 Earnings & Revenue Beat, 2024 EPS View Up
QGEN delivers another solid performance in the third quarter of 2024, with both the top and bottom lines surpassing estimates.
Compared to Estimates, Qiagen (QGEN) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Qiagen (QGEN) Q3 Earnings and Revenues Top Estimates
Qiagen (QGEN) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.54 per share. This compares to earnings of $0.52 per share a year ago.
Diagnostics firm Qiagen reports rise in third-quarter revenue
Qiagen reported a rise in third-quarter revenue on Wednesday, owing to strong sales of its diagnostic devices.
QGEN Stock Set to Gain From FDA's Clearance of QIAstat-Dx Mini Panel
QIAGEN wins FDA clearance for the QIAstat-Dx mini panel to improve precision in outpatient respiratory treatment.
Qiagen (QGEN) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Beyond analysts' top -and-bottom-line estimates for Qiagen (QGEN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2024.
Reasons to Retain QIAGEN Stock in Your Portfolio for Now
Investors feel optimistic about QGEN's strong growth prospects in the NGS platforms. Yet, an unfavorable currency impact on the company's operations is cornering.
QIAGEN Launches QIAcuityDx Digital PCR System: Stock to Gain?
QGEN expands its digital PCR portfolio with the newly launched QIAcuityDx Digital PCR System. The system will be used for clinical testing in oncology across North America and Europe.
QGEN Stock to Gain From New IVDR Win for QIAstat-Dx Systems and Panels
QIAGEN receives European IVDR certification for QIAstat-Dx syndromic testing instruments and assays.
QIAGEN Stock Likely to Gain From PreAnalytiX's Newly Launched PAXgene
PreAnalytiX, a joint venture of QGEN and BD, introduces the PAXgene Urine Liquid Biopsy Set. QGEN will commercialize the latest set.
